$2.47
2.71% today
Nasdaq, Apr 02, 09:18 pm CET
ISIN
US00091E1091
Symbol
ABSI

Absci Corp Stock price

$2.40
-1.02 29.82% 1M
-1.22 33.70% 6M
-0.22 8.40% YTD
-3.21 57.22% 1Y
-6.42 72.79% 3Y
-13.60 85.00% 5Y
-13.60 85.00% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.11 4.38%
ISIN
US00091E1091
Symbol
ABSI
Sector
Industry

Key metrics

Market capitalization $305.60m
Enterprise Value $187.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 41.36
P/S ratio (TTM) P/S ratio 67.46
P/B ratio (TTM) P/B ratio 1.55
Revenue growth (TTM) Revenue growth -20.71%
Revenue (TTM) Revenue $4.53m
EBIT (operating result TTM) EBIT $-108.89m
Free Cash Flow (TTM) Free Cash Flow $-72.81m
Cash position $128.37m
EPS (TTM) EPS $-0.93
P/E forward negative
P/S forward 26.82
EV/Sales forward 16.44
Short interest 20.82%
Show more

Is Absci Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Absci Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Absci Corp forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Absci Corp forecast:

Buy
100%

Financial data from Absci Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4.53 4.53
21% 21%
100%
- Direct Costs 13 13
4% 4%
296%
-8.86 -8.86
7% 7%
-196%
- Selling and Administrative Expenses 23 23
4% 4%
503%
- Research and Development Expense 64 64
34% 34%
1,410%
-96 -96
20% 20%
-2,108%
- Depreciation and Amortization 13 13
4% 4%
296%
EBIT (Operating Income) EBIT -109 -109
16% 16%
-2,404%
Net Profit -103 -103
7% 7%
-2,276%

In millions USD.

Don't miss a Thing! We will send you all news about Absci Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Absci Corp Stock News

Positive
MarketBeat
2 days ago
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.
Neutral
GlobeNewsWire
7 days ago
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
Neutral
Seeking Alpha
15 days ago
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and CBO Christian Stegmann - SVP of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Vikram Purohit - Morgan Stanley Gil Blum - Needham & Company Debanjana Chatterjee - Jone...
More Absci Corp News

Company Profile

AbSci Corp. engages in the development of protein biomanufacturing technology. It offers SoluPro, an all-in-one protein expression platform which produces complex proteins using simplest and least expensive organism. The company was founded by Sean Mcclain and Mark Valasek in 2011 and is headquartered in Vancouver, WA.

Head office United States
CEO Sean McClain
Employees 157
Founded 2011
Website www.absci.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today